Welcom ku Sichuan Hengkang Science and Technology Development Co., Ltd.

Pa February 15, 2022, US Food and Drug Administration (FDA) idavomereza adagrassib new drug application (NDA) yochizira odwala omwe ali ndi khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC) ndi kusintha kwa KRAS G12C omwe adalandira njira imodzi yokha. chithandizo kale.Pansi pa lamulo la chindapusa cha ogwiritsa ntchito mankhwala, owongolera adzasankha kugwiritsa ntchito pofika Disembala 14, 2022.

M'mbuyomu, mu June 2021, US FDA idapereka chidziwitso cha chithandizo cha adagrassib pochiza odwala omwe ali ndi khansa ya m'mapapo yopanda maselo yaying'ono yonyamula kusintha kwa KRAS G12C.

Adagrassib ndi choletsa champhamvu chapakamwa cha KRAS G12C chodziwika bwino kwambiri.Imamangiriza mosasinthika komanso mosankha ku KRAS G12C ndikuyitseka kuti isagwire ntchito.Ali ndi theka la moyo wautali kuti akwaniritse zoletsa za KRAS zokhazikika komanso zopitirirabe ndipo zimatsogolera kuzinthu zakuya komanso zotsalira za antitumor.

cdcs

Dzina lodziwika: adagrassib

Kodi: mrtx849

Cholinga: KRAS G12C

Kuvomerezedwa koyamba ku United States: sikuvomerezedwa

Kuvomerezedwa koyamba ku China: sikuvomerezedwa

Main Raw material: (R) -3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER (CAS: 278788-66-2)

Mapeto

Ndizodziwika bwino kuti masinthidwe a KRAS ndi ovuta kutsata ndipo ali ndi njira zochepa zochiritsira m'mbiri, makamaka KRAS G12C biomarkers amagwirizanitsidwa ndi zotsatira zosauka za kupulumuka.Nthawi ino, kuwunika kwa FDA pakugwiritsa ntchito mankhwala atsopano a adagrassib kukuwonetsa kupita patsogolo kofunikira popereka zosankha zatsopano komanso zomwe akuyembekezera odwala a KRAS G12C osinthika a NSCLC.

Kochokera:

https://www.onclive.com

https://ir.mirati.com


Nthawi yotumiza: Apr-11-2022